Kyverna Therapeutics, Inc.
KYTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $30 | $36 | $37 | $33 |
| G&A Expenses | $0 | $9 | $10 | $0 |
| SG&A Expenses | $8 | $9 | $10 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | -$1 | $0 |
| Operating Expenses | $38 | $44 | $47 | $40 |
| Operating Income | -$39 | -$44 | -$47 | -$41 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $3 | $4 |
| Pre-Tax Income | -$37 | -$42 | -$45 | -$37 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$37 | -$42 | -$45 | -$37 |
| % Margin | – | – | – | – |
| EPS | -0.85 | -0.97 | -1.03 | -0.87 |
| % Growth | 12.4% | 5.8% | -18.4% | – |
| EPS Diluted | -0.85 | -0.97 | -1.03 | -0.87 |
| Weighted Avg Shares Out | 43 | 43 | 43 | 43 |
| Weighted Avg Shares Out Dil | 43 | 43 | 43 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $3 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$36 | -$42 | -$44 | -$37 |
| % Margin | – | – | – | – |